Topiramate | Cutis (Azurity) | ||
25 mg/mL; Oral Solution |
Less Than $1000 mn
|
||
Less Than 5
|
Less Than 5
|
||
None | None | ||
Less Than 5
|
None | ||
EPRONTIA is indicated for: 1) Epilepsy: Initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older ; adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with LennoxGastaut syndrome in patients 2 years of age and older. 2) Preventive treatment of migraine in patients 12 years of age and older. | |||
Yes
|
Eprontia | Patent 1 |
---|---|
***** | ******* |
Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
---|---|---|---|---|---|
***** | *** / *** | *** **, **** | ******* | ******** | ******* *** **** *** *** **** |